Different Ways of Working Tailor Mayzent for Early SPMS Patients, Novartis Says

Different Ways of Working Tailor Mayzent for Early SPMS Patients, Novartis Says

Publication date: Apr 10, 2019

This post was originally published on this site The effectiveness of Mayzent (siponimod) in both the brain and the body make it an oral therapy tailored for people with early secondary progressive multiple sclerosis (SPMS), according to Dan Bar-Zohar, MD, top executive with Novartis, the treatment’s developer. That’s because Mayzent enters the brain -avidly,” Fox and Bar-Zohar said, where two cell types implicated in the accumulation of injury contain high levels of S1P5: astrocytes, involved in the formation of the blood-brain barrier, and oligodendrocytes, the cells that form the myelin sheet around nerve fibers. This work -suggests that Mayzent has beneficial effects through these cells, through .. . astrocyctes and through oligodendrocytes in order to ameliorate clinical symptoms of progressive disease,” Bar-Zohar said. Likely future trials Novartis is planning to test the therapy in pediatric patients after it concludes ongoing discussions with the European Medicines Agency regarding Mayzent’s approval in Europe. The company is currently conducting a Phase 3 study in the U. S., named EXCHANGE (NCT03623243), assessomg the safety and tolerability of switching patients from other disease-modifying therapies to Mayzent. A future trial, still in planning phases, aims to look at the benefits of identifying SPMS early and starting treatment with Mayzent compared to keeping patients on their current therapy. The post Different Ways of Working Tailor Mayzent for Early SPMS Patients, Novartis Says appeared first on Multiple Sclerosis News Today.

Concepts Keywords
Affinity Neuroscience
Algorithm S1PR1
Astrocytes Sphingosine-1-phosphate
Blood Brain Barrier Siponimod
Brain Novartis
Clinical Medicine Immunosuppressants
Clinical Trial Fingolimod
Europe Diols
European Medicines Agency Medicine
FDA Immunology
Fingolimod Medical specialties
Fox Lipids
Gilenya Multiple sclerosis
Inflammation Oral therapy
Lymph Nodes Therapeutic multiple sclerosis
Lymphocytes Accumulation injury
Microglia MS
Multiple Sclerosis
Myelin
Nerve
Nerve Cells
Neurologist
Neurons
Neuroscience
Novartis
Oligodendrocytes
Pediatric
Pharmacological
Progressive
S1P
Slowed Heart Rate
Time
Tolerability
Zohar

Semantics

Type Source Name
drug DRUGBANK Tropicamide
drug DRUGBANK Dimethyl fumarate
disease MESH inflammation
gene UNIPROT S1PR5
gene UNIPROT S1PR1
drug DRUGBANK Fingolimod
gene UNIPROT MBTPS1
drug DRUGBANK Nonoxynol-9
disease MESH development
gene UNIPROT MAGEE1
disease DOID RRMS
disease DOID multiple sclerosis
disease MESH multiple sclerosis
gene UNIPROT THOP1
gene UNIPROT NR1H4
gene UNIPROT ADRB2
gene UNIPROT BFAR
gene UNIPROT PARN
gene UNIPROT NBL1
disease MESH secondary progressive multiple sclerosis
disease DOID SPMS
gene UNIPROT SLC35G1
drug DRUGBANK Siponimod

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *